Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biovie Inc (OP: BIVI)
0.0425 USD  -0.0055 (-11.46%)
Official Closing Price  /  Updated: 3:35 PM EDT, Oct 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 124,700
Open 0.0404
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0480
Today's Range 0.0400 - 0.0459
52wk Range 0.0211 - 0.1400
Shares Outstanding 97,334,699
Dividend Yield N/A
Performance
YTD
+19.72%
+19.72%
1 Month
-43.33%
-43.33%
3 Month
-55.26%
-55.26%
6 Month
-41.46%
-41.46%
1 Year
-15.00%
-15.00%
Top News
More News
BriaCell Appoints Richard J. Berman to Board of Directors
from GlobeNewswire News Releases
BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of... Read More
from GlobeNewswire News Releases
More News
Read More
BioVie to Present at ThinkEquity Conference in NYC on May 2nd
from GlobeNewswire News Releases
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
from GlobeNewswire News Releases
BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS)
from ACCESSWIRE
BioVie Inc. (OTCQB:BIVI) Attains Milestone
from GlobeNewswire News Releases
BioVie to Present at The MicroCap Conference in New York on April 9th
from GlobeNewswire News Releases
BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline
from GlobeNewswire News Releases
BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis
from Marketwired News Releases
BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial; First Patient Completes 28-day Treatment Regimen
from Marketwired News Releases
Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock
from Marketwired News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.